Ziqian Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ziqian Wang has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Zhichao Zhang
Central Hospital of Dalian University of Technology, School of Pharmacy, Faculty of Medicine, Dalian University of Technology, Dalian, Liaoning 116024, China
4 shared publications Fangkui Yin
Cancer Hospital of Dalian University of Technology, School of Chemistry, Dalian University of Technology, Dalian, Liaoning, China 116024
3 shared publicationsHong Zhang
Central Hospital of Dalian University of Technology, Dalian University of Technology, Dalian, Liaoning, China 116024
3 shared publicationsMaojun Jiang
Cancer Hospital of Dalian University of Technology, School of Chemistry, Dalian University of Technology, Dalian, Liaoning, China 116024
3 shared publicationsTing Song
Cancer Hospital of Dalian University of Technology, School of Pharmacy, Faculty of Medicine, Dalian University of Technology, Dalian, Liaoning, China 116024
2 shared publicationsYang Song
Central Hospital of Dalian University of Technology, Dalian University of Technology, Dalian, Liaoning, China 116024
2 shared publications
Latest Publications
- 14 March 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 393, 114828
The HSP90-dependent bioorthogonal PROTAC prodrug system enables tumor-selective and enhanced protein degradation
- 14 March 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 393, 114828
The HSP90-dependent bioorthogonal PROTAC prodrug system enables tumor-selective and enhanced protein degradation
- 16 April 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 310, 143249
A kinase-independent Bcr-Abl function mediating an Hsp70-Bim protein-protein interaction in chronic myeloid leukemia
- 16 April 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 310, 143249
A kinase-independent Bcr-Abl function mediating an Hsp70-Bim protein-protein interaction in chronic myeloid leukemia
- 13 February 2024
- Published by Springer Nature in Journal of Molecular Modeling
- Vol. 30 (3) , 1-7
Exploring the binding mechanism of a small molecular Hsp70-Bim PPI inhibitor through molecular dynamic simulation
Context The interface of Hsp70-Bim protein–protein interaction (PPI) has been identified as a specific target for Chronic Myeloid Leukemia (CML) therapy and the specific inhibitors were developed to exhibit in vivo anti-leukemia activities. Herein, we explored the binding mechanism of a Hsp70-Bim inhibitor, 6-(cyclohexylthio)-3-((2-morpholinoethyl) amino)-1-oxo-1H-phenalene-2-carbonitrile (S1g-6), to Hsp70 at the atomic level by MD simulation. TYR-149, THR-222, ALA-223, and GLY-224 on Hsp70 were identified as four key residues that contribute to Hsp70/S1g-6 complex. Moreover, the site mutation validation demonstrated the TYR-149 of Hsp70 is a “hot-spot” in the Hsp70-Bim PPI interface. These results could benefit the design of further inhibitors to occupy the Bim binding site on the Hsp70 surface. Methods The binding mechanism of S1g-6 and Hsp70 was predicted through the molecular dynamics (MD) method by Gromacs-2021.3. The MD simulation was performed with 100-ps NVT and 100-ps NPT ensemble, and the force field was chosen as the Charmm36 force field. The temperature was set as 300 K, the time step was 2 fs and the total MD simulation time was 500 ns.
- 13 February 2024
- Published by Springer Nature in Journal of Molecular Modeling
- Vol. 30 (3) , 1-7
Exploring the binding mechanism of a small molecular Hsp70-Bim PPI inhibitor through molecular dynamic simulation
Context The interface of Hsp70-Bim protein–protein interaction (PPI) has been identified as a specific target for Chronic Myeloid Leukemia (CML) therapy and the specific inhibitors were developed to exhibit in vivo anti-leukemia activities. Herein, we explored the binding mechanism of a Hsp70-Bim inhibitor, 6-(cyclohexylthio)-3-((2-morpholinoethyl) amino)-1-oxo-1H-phenalene-2-carbonitrile (S1g-6), to Hsp70 at the atomic level by MD simulation. TYR-149, THR-222, ALA-223, and GLY-224 on Hsp70 were identified as four key residues that contribute to Hsp70/S1g-6 complex. Moreover, the site mutation validation demonstrated the TYR-149 of Hsp70 is a “hot-spot” in the Hsp70-Bim PPI interface. These results could benefit the design of further inhibitors to occupy the Bim binding site on the Hsp70 surface. Methods The binding mechanism of S1g-6 and Hsp70 was predicted through the molecular dynamics (MD) method by Gromacs-2021.3. The MD simulation was performed with 100-ps NVT and 100-ps NPT ensemble, and the force field was chosen as the Charmm36 force field. The temperature was set as 300 K, the time step was 2 fs and the total MD simulation time was 500 ns.
- 28 May 2022
- Published by Springer Nature in Pharmaceutical Chemistry Journal
- Vol. 56 (3) , 329-338
Structure-Based Design and Structure-Activity Relationship Analysis of Small Molecules Inhibiting Bcl-2 Family Members
- 28 May 2022
- Published by Springer Nature in Pharmaceutical Chemistry Journal
- Vol. 56 (3) , 329-338
Structure-Based Design and Structure-Activity Relationship Analysis of Small Molecules Inhibiting Bcl-2 Family Members
- 1 May 2019
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 512 (4) , 921-926
Discovery of selective Mcl-1 inhibitors via structure-based design and structure-activity relationship analysis
- 1 May 2019
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 512 (4) , 921-926
Discovery of selective Mcl-1 inhibitors via structure-based design and structure-activity relationship analysis